News Events


Paras Biopharmaceuticals acquires new Aglient Q-TOF to expand analytical capabilities

12th January 2016: Paras Biopharmaceuticals has announced the expansion of its analytical capabilities with the procurement of a Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) and UHPLC systems for peptide identification. This devices provides exceptional MS and MS/MS performance without compromises and will allow Paras to add to its existing analytical suite.



Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland

Based on their products and its continuous drive to push the limits of Quality with innovations, Paras Biopharmaceuticals has received the ESQR’s Quality Choice Prize 2016 for their hard work and achievements, in the presence of the international business community for its commitment to quality, excellence and continuous improvement. 12th December 2016 in Berlin, Germany



Biochemistry Students participate in fact-finding tour of GMP facility

As part of Paras Biopharmaceuticals' corporate social responsibility initiative to encourage students into the fields of biochemistry and biopharmaceutical production, on 18th November 2016 Paras Biopharmaceuticals welcomed Histoni Ry and its members to its Oulu-based facility. Histoni Ry is the student organisation of the biochemistry department at the University of Oulu.



Paras Biopharmaceuticals upgrades its purification suite to expand existing capabilities.

19th September 2016. Paras Biopharmaceuticals expands its purification suite with the addition of low-pressure AxiChrom columns from GE Healthcare Life Sciences. The most notable addition is the AxiChrom 300 column and AxiChrom Packing Master.



Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.

25th August 2016, - Oulu-based Paras Biopharmaceuticals Finland Oy has developed technology for the production of an osteoporosis drug (Recombinant Teriparatide) which will result into a very economical production of the medicine. International pharma companies are actively in discussions with Paras Biopharmaceuticals to further take regulatory work and bring the medicine to market.



Paras forms partnership with Novozymes (Denmark)

In collaboration with Novozymes (Denmark), Paras Biopharmaceuticals (Finland) announced that the partnership will use the successful VELTIS® technology to develop an improved version of a leading osteoporosis treatment. 24th November 2015



Paras’ corporate social responsibility initiative

Biotechnology students from the University of Oulu take up the chance to explore Paras’ facilities. 12th November 2015



Paras wins international award

On 11th December 2014 in Frankfurt, Germany, senior members of the Paras Team received an international award by the US company Frost & Sullivan.



Paras in the news: “Oulu doesn’t give up”

Reported on 7th Aug 2014 by Helsinki-based business newspaper “Kauppalehti”



Paras’ corporate social responsibility initiative

8th grade students from Oulu International School take up the chance to explore Paras’ facilities. 22th April 2014



Paras’ corporate social responsibility initiative

Biotechnology students from Tampere University of Technology take up the chance to explore Paras’ facilities. 28th March 2014



Paras in the news: “Medicine cost down using Oulu-based knowledge”

Reported by Oulu’s local newspaper “Kaleva” (13th October 2013)



Media Contact

Dr. Mark Jackson
Public Affairs
mark.jackson@parasbiopharma.com